G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease

G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease

Objective(s): Granulocyte-colony stimulating factor (G-CSF) is used in clinical practice for the treatment of neutropenia and to stimulate generation of hematopoietic stem cells in bone marrow donors. In the present study, the ability of G-CSF in mobilizing exogenous bone marrow stem cells (BMSCs) f...

Full description

Bibliographic Details
Main Authors:	Manouchehr Safari, Behnaz Jafari, Sam Zarbakhsh, Hamidreza Sameni, Abbas Ali Vafaei, Nasrin Khan Mohammadi, Laya Ghahari
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2016-12-01
Series:	Iranian Journal of Basic Medical Sciences
Subjects:	Bone marrow stem cells Dopaminergic neurons Granulocyte colony stimulating factor Parkinson
Online Access:	http://ijbms.mums.ac.ir/article_7918_a417b9fe1c4b06c5d0648f44ab70dc93.pdf

Similar Items

Mesenchymal stem cells that located in the electromagnetic fields improves rat model of Parkinson's disease
by: Majid Jadidi, et al.
Published: (2016-07-01)

Mesenchymal Stem Cells with Granulocyte Colony-Stimulating Factor Reduce Stress Oxidative Factors in Parkinson\'s Disease
by: Laya Ghahari, et al.
Published: (2020-03-01)

Bone Marrow Stromal Cells with the Granulocyte Colony-Stimulating Factor in the Management of Chemotherapy-Induced Ovarian Failure in a Rat Model
by: Hamid Reza Sameni, et al.
Published: (2019-03-01)

Studying the Pathophysiology of Parkinson’s Disease Using Zebrafish
by: Lisa M. Barnhill, et al.
Published: (2020-07-01)

Roles of stem cells in the treatment of Parkinson's disease
by: Yasaman Ebrahimikia, et al.
Published: (2018-10-01)

Caffeic Acid Phenethyl Ester With Mesenchymal Stem Cells Improves Behavioral and Histopathological Changes in the Rat Model of Parkinson Disease
by: Khojasteh Rahimi Jaberi, et al.
Published: (2022-09-01)

Excessive Daytime Sleepiness in Parkinson’s Disease
by: Liu H, et al.
Published: (2022-09-01)

Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials
by: Jang, Se Eun, et al.
Published: (2021)

Animal Models of Autosomal Recessive Parkinsonism
by: Guendalina Bastioli, et al.
Published: (2021-07-01)

Irisin protect the Dopaminergic neurons of the Substantia nigra in the rat model of Parkinson’s disease
by: Sam Zarbakhsh, et al.
Published: (2019-07-01)

A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
by: Giselle Prunell, et al.
Published: (2022-11-01)

Parkinson’s disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010-11-01)

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
by: Ming-Wei Lin, et al.
Published: (2019-12-01)

Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
by: Leonie M. Heger, et al.
Published: (2021-12-01)

Effects of Co-Administration of Bone Marrow Stromal Cells and L-Carnitine on The Recovery of Damaged Ovaries by Performing Chemotherapy Model in Rat
by: Sam Zarbakhsh, et al.
Published: (2019-10-01)

Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease
by: E Chang, et al.
Published: (2021-08-01)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
by: Kai He, et al.
Published: (2022-07-01)

Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements
by: Longping Yao, et al.
Published: (2021-07-01)

The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis
by: Viviana A. Ruiz-Pozo, et al.
Published: (2023-08-01)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
by: Xin He, et al.
Published: (2021-11-01)

Understanding miRNA Based Gene Regulation in Parkinson’s Disease: An in silico Approach
by: Surya Narayan Rath, et al.
Published: (2020-03-01)

Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01)

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson’s Disease Model
by: Ruru Jia, et al.
Published: (2023-02-01)

Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson’s Disease
by: Anna Kolacheva, et al.
Published: (2022-12-01)

Neuroprotective potential of Afzelin: A novel approach for alleviating catalepsy and modulating Bcl-2 expression in Parkinson's disease therapy
by: Khalid M. Alharthy, et al.
Published: (2024-02-01)

Triggering Receptor Expressed on Myeloid Cells 2 Protects Dopaminergic Neurons by Promoting Autophagy in the Inflammatory Pathogenesis of Parkinson’s Disease
by: Wei Huang, et al.
Published: (2021-11-01)

Downregulation of Ambra1 by altered DNA methylation exacerbates dopaminergic neuron damage in a fenpropathrin-induced Parkinson-like mouse model
by: Songzhe He, et al.
Published: (2024-02-01)

Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01)

A novel curcumin oil solution can better alleviate the motor activity defects and neuropathological damage of a Parkinson’s disease mouse model
by: Xiwen Geng, et al.
Published: (2022-07-01)

The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement
by: Hanwen Zhang, et al.
Published: (2022-06-01)

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage
by: Elena A. Katunina, et al.
Published: (2023-01-01)

Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease
by: Christelle Lasbleiz, et al.
Published: (2019-02-01)

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease
by: Ramesh Pariyar, et al.
Published: (2022-02-01)

Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson’s Disease
by: Vandana Zaman, et al.
Published: (2022-11-01)

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
by: Atsushi Fujita, et al.
Published: (2018-08-01)

Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson’s disease
by: Julian L. Goggi, et al.
Published: (2020-08-01)

Acrylamide-induced changes of granulopoiesis in porcine bone marrow
by: Grzybowska Dominika, et al.
Published: (2021-07-01)

Transient thrombocytopenia in a cat following G‐CSF treatment
by: Kyeong‐Bo Kim, et al.
Published: (2022-03-01)

The role of NURR1 in metabolic abnormalities of Parkinson’s disease
by: Murad Al-Nusaif, et al.
Published: (2022-06-01)

Roles of FGF20 in dopaminergic neurons and Parkinson’s disease
by: Nobuyuki eItoh, et al.
Published: (2013-05-01)